Teladoc Inc (TDOC)

$13.74

+0.44

(+3.31%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Teladoc Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 629.24M → 660.52M (in $), with an average increase of 1.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -3.81B → -28.89M (in $), with an average increase of 1380.4% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 41.9% return, outperforming this stock by 93.1%

  • Vs HQY

    In the last 3 years, Healthequity Inc has given 8.6% return, outperforming this stock by 101.1%

Performance

  • $13.33
    $14.03
    $13.74
    downward going graph

    3.02%

    Downside

    Day's Volatility :5.02%

    Upside

    2.07%

    downward going graph
  • $12.86
    $30.41
    $13.74
    downward going graph

    6.4%

    Downside

    52 Weeks Volatility :57.71%

    Upside

    54.82%

    downward going graph

Returns

PeriodTeladoc IncSector (Health Care)Index (Russel 2000)
3 Months
-31.95%
1.9%
0.0%
6 Months
-24.17%
10.7%
0.0%
1 Year
-51.22%
4.6%
-1.1%
3 Years
-92.77%
14.2%
-22.1%

Highlights

Market Capitalization
2.3B
Book Value
$13.96
Earnings Per Share (EPS)
-1.34
PEG Ratio
-1.01
Wall Street Target Price
19.7
Profit Margin
-8.47%
Operating Margin TTM
-4.53%
Return On Assets TTM
-3.01%
Return On Equity TTM
-9.51%
Revenue TTM
2.6B
Revenue Per Share TTM
15.81
Quarterly Revenue Growth YOY
3.5999999999999996%
Gross Profit TTM
1.7B
EBITDA
46.2M
Diluted Eps TTM
-1.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.04
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Hold
    31%Buy
    68%Hold
    0
    0%Sell
Based on 32 Wall street analysts offering stock ratings for Teladoc Inc(by analysts ranked 0 to 5 stars)
Based on 32 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
22
22
24
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 43.38%

Current $13.74
Target $19.70

Company Financials

FY18Y/Y Change
Revenue
417.9M
↑ 79.14%
Net Income
-97.1M
↓ 9.08%
Net Profit Margin
-23.23%
↑ 22.54%
FY19Y/Y Change
Revenue
553.3M
↑ 32.4%
Net Income
-98.9M
↑ 1.83%
Net Profit Margin
-17.87%
↑ 5.36%
FY20Y/Y Change
Revenue
1.1B
↑ 97.71%
Net Income
-485.1M
↑ 390.71%
Net Profit Margin
-44.35%
↓ 26.48%
FY21Y/Y Change
Revenue
2.0B
↑ 85.81%
Net Income
-428.8M
↓ 11.61%
Net Profit Margin
-21.09%
↑ 23.26%
FY22Y/Y Change
Revenue
2.4B
↑ 18.41%
Net Income
-13.7B
↑ 3085.58%
Net Profit Margin
-567.53%
↓ 546.44%
FY23Y/Y Change
Revenue
2.6B
↑ 8.13%
Net Income
-220.4M
↓ 98.39%
Net Profit Margin
-8.47%
↑ 559.06%
Q3 FY22Q/Q Change
Revenue
611.4M
↑ 3.21%
Net Income
-73.5M
↓ 97.63%
Net Profit Margin
-12.02%
↑ 511.54%
Q4 FY22Q/Q Change
Revenue
637.7M
↑ 4.3%
Net Income
-3.8B
↑ 5085.46%
Net Profit Margin
-597.46%
↓ 585.44%
Q1 FY23Q/Q Change
Revenue
629.2M
↓ 1.33%
Net Income
-69.2M
↓ 98.18%
Net Profit Margin
-11.0%
↑ 586.46%
Q2 FY23Q/Q Change
Revenue
652.4M
↑ 3.68%
Net Income
-65.2M
↓ 5.85%
Net Profit Margin
-9.99%
↑ 1.01%
Q3 FY23Q/Q Change
Revenue
660.2M
↑ 1.2%
Net Income
-57.1M
↓ 12.43%
Net Profit Margin
-8.64%
↑ 1.35%
Q4 FY23Q/Q Change
Revenue
660.5M
↑ 0.04%
Net Income
-28.9M
↓ 49.38%
Net Profit Margin
-4.37%
↑ 4.27%
FY18Y/Y Change
Total Assets
1.5B
↑ 85.46%
Total Liabilities
515.8M
↑ 94.27%
FY19Y/Y Change
Total Assets
1.6B
↑ 4.84%
Total Liabilities
588.8M
↑ 14.16%
FY20Y/Y Change
Total Assets
17.8B
↑ 1007.75%
Total Liabilities
1.9B
↑ 217.84%
FY21Y/Y Change
Total Assets
17.7B
↓ 0.12%
Total Liabilities
1.7B
↓ 9.76%
FY22Y/Y Change
Total Assets
4.3B
↓ 75.5%
Total Liabilities
2.0B
↑ 20.65%
FY23Y/Y Change
Total Assets
4.4B
↑ 1.08%
Total Liabilities
2.1B
↑ 1.41%
Q3 FY22Q/Q Change
Total Assets
8.1B
↑ 0.01%
Total Liabilities
2.1B
↑ 1.64%
Q4 FY22Q/Q Change
Total Assets
4.3B
↓ 46.38%
Total Liabilities
2.0B
↓ 0.67%
Q1 FY23Q/Q Change
Total Assets
4.3B
↓ 0.83%
Total Liabilities
2.0B
↓ 0.97%
Q2 FY23Q/Q Change
Total Assets
4.3B
↑ 0.17%
Total Liabilities
2.0B
↑ 0.17%
Q3 FY23Q/Q Change
Total Assets
4.3B
↑ 0.27%
Total Liabilities
2.0B
↑ 0.63%
Q4 FY23Q/Q Change
Total Assets
4.4B
↑ 1.49%
Total Liabilities
2.1B
↑ 1.59%
FY18Y/Y Change
Operating Cash Flow
-4.9M
↓ 85.89%
Investing Cash Flow
-257.5M
↓ 42.57%
Financing Cash Flow
645.6M
↑ 35.8%
FY19Y/Y Change
Operating Cash Flow
29.9M
↓ 714.59%
Investing Cash Flow
25.0M
↓ 109.71%
Financing Cash Flow
35.1M
↓ 94.56%
FY20Y/Y Change
Operating Cash Flow
-53.5M
↓ 279.15%
Investing Cash Flow
-591.0M
↓ 2462.67%
Financing Cash Flow
859.1M
↑ 2348.1%
FY21Y/Y Change
Operating Cash Flow
194.0M
↓ 462.52%
Investing Cash Flow
-73.0M
↓ 87.65%
Financing Cash Flow
40.9M
↓ 95.23%
FY22Y/Y Change
Operating Cash Flow
189.3M
↓ 2.42%
Investing Cash Flow
-167.7M
↑ 129.84%
Financing Cash Flow
6.5M
↓ 84.13%
Q3 FY22Q/Q Change
Operating Cash Flow
63.0M
↓ 31.85%
Investing Cash Flow
-41.4M
↓ 7.56%
Financing Cash Flow
634.0K
↓ 147.53%
Q4 FY22Q/Q Change
Operating Cash Flow
65.5M
↑ 4.01%
Investing Cash Flow
-53.9M
↑ 30.02%
Financing Cash Flow
4.4M
↑ 591.01%
Q1 FY23Q/Q Change
Operating Cash Flow
13.2M
↓ 79.93%
Investing Cash Flow
-45.6M
↓ 15.34%
Financing Cash Flow
3.4M
↓ 23.46%
Q2 FY23Q/Q Change
Operating Cash Flow
101.2M
↑ 669.09%
Investing Cash Flow
-36.6M
↓ 19.84%
Financing Cash Flow
4.2M
↑ 25.5%
Q3 FY23Q/Q Change
Operating Cash Flow
105.6M
↑ 4.37%
Investing Cash Flow
-37.6M
↑ 2.95%
Financing Cash Flow
5.1M
↑ 20.44%

Technicals Summary

Sell

Neutral

Buy

Teladoc Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Teladoc Inc
Teladoc Inc
-8.89%
-24.17%
-51.22%
-92.77%
-74.77%
Solventum Corp
Solventum Corp
-8.1%
-8.1%
-8.1%
-8.1%
-8.1%
Veeva Systems Inc.
Veeva Systems Inc.
-12.34%
1.98%
7.91%
-29.07%
47.16%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-2.31%
33.35%
-1.77%
42.57%
42.57%
Healthequity Inc
Healthequity Inc
0.62%
11.22%
41.89%
4.64%
13.16%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Teladoc Inc
Teladoc Inc
NA
NA
-1.01
-1.04
-0.1
-0.03
NA
13.96
Solventum Corp
Solventum Corp
NA
NA
NA
0.0
0.12
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
61.82
61.82
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
28.4
28.4
20.11
4.3
0.19
0.06
0.0
15.67
Healthequity Inc
Healthequity Inc
126.86
126.86
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Teladoc Inc
Teladoc Inc
Hold
$2.3B
-74.77%
NA
-8.47%
Solventum Corp
Solventum Corp
NA
$11.7B
-8.1%
NA
16.42%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.1B
47.16%
61.82
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.4B
42.57%
28.4
8.02%
Healthequity Inc
Healthequity Inc
Buy
$7.0B
13.16%
126.86
5.57%

Institutional Holdings

  • ARK Investment Management LLC

    12.54%

  • Vanguard Group Inc

    10.34%

  • BlackRock Inc

    7.76%

  • Nikko Asset Management Americas Inc

    4.41%

  • Sumitomo Mitsui Trust Holdings Inc

    4.24%

  • State Street Corporation

    3.18%

Corporate Announcements

  • Teladoc Inc Earnings

    Teladoc Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Teladoc Health Inc. founded by G. Byron Brooks and Michael Gorton is a multinational company for telemedicine and virtual healthcare in America. The company was incorporated in 2002 in Dallas, Texas, USA. Teladoc Health Inc. is headquartered in Purchase, New York, USA, and operates in more than 130 countries worldwide. The company has over 4,400 employees serving across the world. Teladoc Health primarily caters to telehealth services and devices, AI and analytics, medical opinions, and licensable platform services. It is the first and largest telemedicine company in the USA to have served 40 million members in 2021 and traded on the New York Stock Exchange as TDOC under the Russel 1000 component. Teledoc Health Inc. has acquired some of the major companies in the past few years such as BetterHelp in 2015, followed by Best Doctors and Advance Medical in 2017 and 2018, respectively. However, the company eventually dropped the lawsuit voluntarily after Texas passed a new bill allowing remote medical treatment without a physical meeting in 2017. In the financial year 2020, Teladoc Health Inc. generated annual revenue of $1.093 billion. Currently Teladoc Inc has a market cap of $2.25 Billion. It has a P.E ratio of -10.22. The shares of Teladoc Inc are trading at $13.74. .

Organization
Teladoc Inc
Employees
4816
CEO
Ms. Mala Murthy
Industry
Health Services

Discover More

FAQs